RxDoctor Payments Data

Lester Shalloway, MD

Internal Medicine · Miami, FLNPI 1083689772

Payments from drug & device makers

$9,637in general payments, 2019–2025

Across 533 payments — averaging $18.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$1K
  • GSK$763
  • Novo Nordisk$703
  • AstraZeneca$687
  • Pfizer$587
  • Amgen$569
  • plus $5K from 54 others

What the payments were for

  • Food & beverage$9,637100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Lilly USA, LLC74$1,130
GSK39$763
Novo Nordisk42$703
AstraZeneca38$687
Pfizer38$587
Amgen31$569
AbbVie(2 entities)29$526
Abbott18$346
Novartis20$330
Antares Pharma, Inc.21$312
Boehringer Ingelheim13$294
Amarin Pharma, Inc.13$243
Bayer8$188
Sumitomo Pharma America, Inc.7$168
Biohaven Pharmaceutical Holding Company Ltd.8$166
Johnson & Johnson10$161
Takeda Pharmaceuticals U.S.A., Inc.7$152
Exact Sciences6$138
Halozyme Inc10$137
Esperion Therapeutics, Inc.6$127
Dexcom, Inc.6$114
Phadia US Inc.7$113
Corcept Therapeutics5$112
Merck5$90
Averitas Pharma Inc.3$88
Phathom Pharmaceuticals, Inc.4$87
Inspire Medical Systems, Inc.2$82
Astellas Pharma US Inc5$78
Verona Pharma, Inc.4$74
Sunovion Pharmaceuticals Inc.3$73
Teva Pharmaceuticals USA, Inc.3$64
Biogen3$63
Alfasigma USA, Inc.3$61
Ardelyx, Inc.3$57
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC3$53
Alnylam Pharmaceuticals Inc.2$53
Sanofi-aventis U.S. LLC3$50
Axsome Therapeutics, Inc.2$49
Viatris Specialty LLC2$46
Hologic Sales And Service, LLC2$36
Electromed, Inc.2$35
Aytu Biopharma, Inc.2$34
Shire North American Group Inc2$33
Idorsia Pharmaceuticals US Inc2$31
Kowa Pharmaceuticals America, Inc.2$30
Insulet Corporation1$29
Insmed, Inc.1$29
Edwards Lifesciences1$29
Sanofi Pasteur Inc.1$24
Boston Scientific1$23
Biohaven Pharmaceuticals, Inc.1$21
Baxter Healthcare1$19
Eisai Inc.1$19
E.r. Squibb & Sons, L.L.C.1$19
Radius Health, Inc.1$18
Azurity Pharmaceuticals, Inc.1$17
Otsuka America Pharmaceutical, Inc.1$17
Coloplast1$14
Currax Pharmaceuticals LLC1$14
Nalpropion Pharmaceuticals LLC1$12

How this compares

$9,637 in reported general payments places this provider in the 90th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$38,398
Medicare patients
107
Services billed
503

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide20$26,031
FarxigaDapagliflozin Propanediol12$14,046
EliquisApixaban13$12,539
VascepaIcosapent Ethyl24$10,614
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen54$1,668
Rosuvastatin Calcium113$1,392
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen27$1,071
Modafinil12$863
Metoprolol Succinate38$707
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine20$655
Omeprazole27$588
Ezetimibe27$582
Atorvastatin Calcium54$405
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine11$377
Levothyroxine Sodium32$362

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$703$26,03120 claims
AstraZenecaFarxiga$687$14,04612 claims
PfizerEliquis$587$12,53913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →